Hong Kong Media Stock News

Bank of China has exercised its redemption right on a RMB 15b tranche of Tier 2 capital bonds issued in 2021. The full redemption affects the bank's mix of regulatory capital and could influence its future funding costs. This move reflects an active approach to managing its capital structure and overall financial flexibility. For investors watching Bank of China (SEHK:3988), this capital action comes with the shares trading at HK$4.84 and showing a 6.8% return year to date and an 11.0%...

Kuaishou Technology (SEHK:1024) has wrapped up FY 2025 with fourth quarter revenue of C¥39.6b and basic EPS of C¥1.22, against trailing 12 month revenue of C¥142.8b and EPS of C¥4.35 that came with 21.4% earnings growth over the prior year. Over recent periods, revenue has moved from C¥35.4b in Q4 2024 to C¥39.6b in Q4 2025, while quarterly basic EPS has shifted from C¥0.93 to C¥1.22, presenting a set of results where a 13% net profit margin and improving earnings trends are front and centre...

Tencent Cloud and CGTrader announced a partnership at MWC 2026 to power an AI driven 3D asset creation workflow. The deal integrates Tencent Cloud's HY 3D Global solution into CGTrader's platform for automated 3D content production. The collaboration targets global clients that rely on large scale 3D libraries for gaming, ecommerce, and virtual experiences. For investors following Tencent Holdings (SEHK:700), this move extends the company further into AI supported content creation, an area...

China Life Insurance (SEHK:2628) has wrapped up FY 2025 with a mixed final quarter, reporting Q4 revenue of CNY 39.3b and a basic EPS loss of CNY 0.48, set against trailing 12 month EPS of CNY 5.45 on revenue of CNY 352.1b. Investors are weighing recent 44.1% earnings growth and a net profit margin of 43.8% against forecasts of an 8.1% annual earnings decline over the next three years. Over recent periods the company has seen quarterly revenue move from CNY 58.9b in Q4 2024 to CNY 64.3b in Q1...

ANTA Sports Products (SEHK:2020) has just posted its FY 2025 numbers, with second half revenue of C¥41.7b, basic EPS of C¥2.36 and net income of C¥6.6b, set against a trailing 12 month picture showing C¥80.2b in revenue, basic EPS of C¥4.89 and net income of C¥13.6b as margins eased from 22% to 16.9%. The company has seen revenue move from C¥37.1b and basic EPS of C¥2.81 in the second half of 2024 to C¥41.7b and C¥2.36 in the second half of 2025. Over the same period, trailing 12 month EPS...

Sunac Services Holdings FY 2025 Earnings Snapshot Sunac Services Holdings (SEHK:1516) has reported its FY 2025 numbers with first half revenue of CN¥3,546.6 million and basic EPS of CN¥0.04, while trailing twelve month revenue sits at CN¥6,816.2 million and EPS at CN¥0.07 as the business moves away from prior losses. Over the last three reported half year periods, revenue has held close to the CN¥3,480 million to CN¥3,550 million range, while EPS has swung from a loss of CN¥0.15 in 1H 2024 to...

CGN Power (SEHK:1816) has wrapped up FY 2025 with fourth quarter revenue of about C¥16.0b and basic EPS of C¥0.023, while trailing twelve month revenue stood at roughly C¥75.7b with EPS of C¥0.193. Over recent periods, quarterly revenue has ranged from about C¥16.0b to C¥20.6b, with basic EPS moving between C¥0.023 and C¥0.06. This sets the backdrop for trailing net income of roughly C¥9.8b. With net profit margins ticking up slightly to 12.9% on a trailing basis, the latest results highlight...

Global markets have been navigating a challenging landscape marked by geopolitical tensions, fluctuating oil prices, and persistent inflation concerns. Amidst this backdrop, the concept of penny stocks remains relevant as these smaller or newer companies can offer unique growth opportunities at lower price points. When backed by strong financial health and solid fundamentals, penny stocks can present underappreciated chances for significant returns.

Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors. These approvals move multiple assets in Akeso's pipeline into clinical and mid stage development. For investors tracking Akeso (SEHK:9926), these clearances come with the stock...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has received IND approval in China for SKB103, its first TAA PD-L1 bispecific antibody-drug conjugate. SKB103 becomes the company’s second bispecific ADC to reach the clinical stage, following SKB571. The candidate is built on Kelun-Biotech’s proprietary OptiDC™ platform and is designed to combine tumor antigen targeting with PD-L1 immune modulation. For investors tracking SEHK:6990, the IND clearance for SKB103 adds another clinical stage...

Amidst a backdrop of heightened uncertainty and inflation risks, Asian markets have been navigating through turbulent waters, influenced by global geopolitical tensions and fluctuating oil prices. Despite these challenges, the allure of penny stocks remains strong for investors seeking affordable entry points with potential for significant growth. Although considered a niche investment area today, penny stocks — typically smaller or newer companies — can offer promising opportunities when...

Earnings jump and dividend decisions put Kingboard Holdings (SEHK:148) in focus Kingboard Holdings (SEHK:148) reported full year 2025 results with higher sales and net income, alongside a larger final dividend and a special dividend. These developments have drawn attention to its recent shareholder payout decisions. See our latest analysis for Kingboard Holdings. Kingboard Holdings’ HK$35.36 share price has seen a 19.54% year to date share price return and a 23.03% 90 day share price return...

Even though Inspur Digital Enterprise Technology Limited ( HKG:596 ) has fallen by 10% over the past week , insiders...

Prosperity Real Estate Investment Trust (SEHK:808) has released its FY 2025 numbers with first half revenue of HK$205.8 million and basic EPS of HK$0.11 loss per unit, while the trailing twelve months point to revenue of HK$408.5 million and basic EPS of HK$0.16 loss. Over the past few reporting periods, the trust has seen revenue move from HK$214.9 million in 1H FY 2024 to HK$210.4 million in 2H FY 2024 and then to HK$205.8 million in 1H FY 2025, alongside basic EPS shifting between a...

As you might know, China Resources Beer (Holdings) Company Limited ( HKG:291 ) last week released its latest yearly...

Geely Automobile Holdings Limited's ( HKG:175 ) solid earnings announcement recently didn't do much to the stock price...

Insiders who bought Zhong Ying International Group Limited ( HKG:8516 ) stock in the last 12 months were richly...

As global markets grapple with heightened uncertainty, inflation risks, and geopolitical tensions, investors are increasingly looking toward stable income sources like dividend stocks. In the Asian market, where economic dynamics remain complex amid these challenges, selecting dividend stocks with solid fundamentals and reliable yields can offer a measure of stability in turbulent times.

Amidst a backdrop of global economic uncertainty and inflation risks, the Asian markets continue to navigate challenges with resilience. For investors willing to look beyond the well-known giants, penny stocks—often representing smaller or newer companies—can still offer intriguing opportunities. Though the term may seem outdated, these stocks can provide value when backed by strong financials and potential for growth.

As you might know, Minth Group Limited ( HKG:425 ) last week released its latest full-year, and things did not turn out...

Last week, you might have seen that China Overseas Grand Oceans Group Limited ( HKG:81 ) released its annual result to...

Zhaojin Mining Industry Company Limited ( HKG:1818 ) shareholders will have a reason to smile today, with the analysts...

Nexteer Automotive Group (SEHK:1316) opened FY 2025 with first half revenue of about US$2.2b and basic EPS of roughly US$0.03, against trailing twelve month figures showing basic EPS of about US$0.04 on revenue of roughly US$4.6b and earnings growth of 65.3% over the past year. Over the last three reported half year periods, revenue has moved from about US$2.1b in 1H FY 2024 to US$2.2b in 1H FY 2025, while basic EPS has shifted from roughly US$0.01 to about US$0.03 as net margins increased...

China Medical System Holdings (SEHK:867) has secured Chinese regulatory approval for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis adult chronic kidney disease patients, expanding its presence in the nephrology segment. See our latest analysis for China Medical System Holdings. The share price is at HK$13.27 after a 1 day share price return of 2.47%. However, the 30 day share price return shows a 14.05% decline, which contrasts with an 82.01% 1 year total shareholder...